John Tsai, M.D., has been Head of Global Drug Development and Chief Medical Officer for Novartis since 2018. He is a member of the Executive Committee of Novartis.
Dr. Tsai joined Novartis from Amgen Inc., where he was chief medical officer and senior vice president of Global Medical from 2017 to 2018, overseeing all clinical and medical functions across multiple sites worldwide. Before joining Amgen in 2017, he spent 11 years at Bristol-Myers Squibb Co. (BMS), most recently as global head of clinical development for marketed products from 2016 to 2017. During his time at BMS, Dr. Tsai also served as a full development team leader in oncology from 2015 to 2016, head of Worldwide Medical from 2014 to 2015, chief medical officer for Europe from 2012 to 2014, vice president of US Medical from 2010 to 2012, and vice president of Cardiovascular Medical from 2006 to 2010.
Dr. Tsai holds a doctor of medicine from the University of Louisville School of Medicine in the United States. He received a Bachelor of Science in electrical engineering from Washington University in St. Louis, also in the US.